US Is Home to More Than 18 Million Cancer Survivors
There were more than 18 million cancer survivors in the United States at the beginning of this year, according to new data.
Skin Cancer News
SKIN CANCER ADVISOR
Skin Cancer News
Prevalence of Cancer Among Pregnant Patients on the Rise
The prevalence of pregnancy with cancer increased 13.8% from 2016 to 2019.
Camrelizumab, Apatinib, and Temozolomide Combo Produces Durable Responses in Acral Melanoma
The overall response rate was 66.7%, and the median duration of response was 17.5 months.
Higher Fish Intake May Increase Melanoma Risk
Higher total fish intake, tuna intake, and nonfried fish intake were all positively linked to the risk of malignant melanoma and melanoma in situ.
Omitting Node Dissection, Adjuvant Therapy May Be Safe for Some With Stage III Melanoma
The estimated 2-year RFS rate for patients with MPR was 93.3% (95% CI, 87.2%-99.9%) after a median follow-up of 27.9 months.
Neoadjuvant Pembrolizumab in Resectable Desmoplastic Melanoma Leads to High pCR Rate
The study population included patients aged 18 years and older who had histologically confirmed desmoplastic melanoma that was resectable.
Triple Combination Active Against CNS Metastases of BRAFV600-Mutated Melanoma
The 3-drug strategy combines targeted therapy against BRAF (vemurafenib) and MEK (cobimetinib), and immunotherapy (atezolizumab).
Toripalimab With Axitinib Active in Treatment-Naive Advanced Mucosal Melanoma
Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.
Camrelizumab, Apatinib, Temozolomide Combination Is Efficacious for Acral Melanoma
In all, 32 patients had a response, translating to an ORR of 66.7%.
Concurrent Therapy Improves Responses, Increases Toxicity in Stage III Melanoma
The higher response rates with concurrent therapy did not translate to improvements in survival.
Adjuvant Pembrolizumab Improved Distant Metastasis-Free Survival in Resected Stage IIB, IIC Melanoma
Pembrolizumab significantly improved distant metastasis-free survival and reduced recurrence in stage IIB and IIC melanoma.
Incidence of Melanoma Diagnosis, Biopsy Parallel Skin Screening Uptake
Researchers sought to determine if the incidence of melanoma diagnoses and biopsies increased with a greater uptake of skin screenings.
Factors ID’d for Self-Exam Compliance Among Melanoma Patients
Younger age, female sex, increased disease severity, and having a significant other to help with exams may improve compliance.
Skin Cancer Awareness Month: Protection Is Prevention
Although skin cancer is one of the most preventable cancers, there are knowledge gaps about sun protection that need to be addressed.
Skin Microbiome Variation: Indicator or Risk Factor for Squamous Cell Carcinoma?
The skin microbiome may serve as biomarker for skin cancer progression.
Nivolumab-Ipilimumab Plus Cryoablation in Pediatric, Young Adult Patients With Relapsed/Refractory Solid Tumors
In a phase 2 study, researchers are investigating the combination of cryoablation and dual checkpoint inhibition.
Immune Checkpoint Inhibitors and Adverse Events in Older Patients With Melanoma
Researchers sought to investigate the connection between immune checkpoint inhibitors (ICIs) and immune- and autoimmune-related adverse events in older patients diagnosed with melanoma.
Guideline Updated for Use of Radiation for Brain Metastases
The updated guideline reviews advanced radiation therapy techniques and places emphasis on multidisciplinary care.
Ban of Indoor Tanning Beds Would Reduce Cancers, Cut Costs
The intervention would yield a net monetary benefit of £10.6 million and a net health benefit of 530 QALYs, researchers found.
Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Skin Cancer
Loading... 
Loading...